Modular Medical, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2023, compared with fiscal 2022. This is an annual report, not a standalone calendar-quarter 2022 report; quarterly Q4 results are not separately provided in the supplied filing text. Filed June 26, 2023.
Business context
Modular Medical is a development-stage medical-device company developing MODD1, a two-part wearable insulin pump intended to simplify pump use and reduce cost. The company had no product revenue and had not received FDA clearance to market MODD1 as of March 31, 2023. It reported 38 employees, including 34 in research and development and manufacturing operations.
Financial performance and position
| Metric | FY2023 / March 31, 2023 | FY2022 / March 31, 2022 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $9.06 million | $7.73 million |
| General and administrative expense | $4.82 million | $7.20 million |
| Total operating expenses / operating loss | $13.88 million | $14.93 million |
| Net loss | $13.88 million | $18.63 million |
| Net loss per share, basic and diluted | $1.28 | $2.74 |
| Cash used in operating activities | $11.01 million | $10.26 million |
| Cash used in investing activities | $1.64 million | $0.05 million |
| Cash provided by financing activities | $7.37 million | $17.92 million |
| Cash and cash equivalents | $3.80 million | $9.08 million |
| Total assets | $7.25 million | $9.85 million |
| Total liabilities | $2.17 million | $1.01 million |
| Accumulated deficit | $48.46 million | $34.58 million |
Gross margin and other operating margins are not meaningful because the company reported no revenue. The company had no convertible or bridge notes outstanding at year-end; liabilities included $1.55 million of lease liabilities. It also reported approximately $833,000 in outstanding machinery and equipment purchase orders.
Material changes versus prior year
- Net loss narrowed by about $4.75 million, largely as fiscal 2022 included $2.75 million of interest expense and a $1.32 million debt-extinguishment loss; neither recurred in fiscal 2023. Operating expenses fell about $1.05 million overall.
- R&D expense rose 17.2%, reflecting higher engineering and operations staffing, stock compensation, and materials costs; the company reduced consulting costs as it expanded internal headcount.
- G&A expense declined 33.1%, mainly due to lower stock-based compensation, personnel costs, and professional fees.
- Operating cash use increased by about $0.75 million despite the smaller net loss. Capital spending rose to $1.64 million, primarily for property and equipment.
- Cash fell by $5.28 million during the year. Financing proceeds were lower than in fiscal 2022, when the company completed a larger public offering and raised debt financing.
Liquidity, outlook, and risks
- Going concern: Management and the independent auditor stated that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after the financial statements were issued. The auditor’s opinion on the financial statements was unqualified, but included a going-concern emphasis.
- Subsequent financing: In May 2023, the company completed an offering of shares and warrants. It reported approximately $9.7 million in net proceeds. The filing says this financing did not eliminate the need for additional capital to fund operations for 12 months from the report date. The offering also created potential shareholder dilution.
- Spending outlook: Management expected R&D and G&A expenses to increase in fiscal 2024, as it continued testing and development, prepared its FDA submission, developed low-volume manufacturing, and expanded the organization.
- Product and regulatory milestones: MODD1 testing and FDA 510(k) submission preparation were ongoing. Required testing includes insulin stability, biocompatibility, occlusion detection, and cybersecurity. FDA clearance, manufacturing transfer and validation, reimbursement, and market acceptance remain necessary for commercialization. Management described a post-clearance soft launch and anticipated a fuller launch in late 2024; these were plans, not achieved milestones.
- Key risks: Continued losses and cash burn; dependence on future financing; risk of delay or failure in FDA clearance; insulin-stability testing history; reliance on third-party manufacturers and suppliers; uncertain reimbursement and adoption; competition from established device companies; and limited intellectual-property protection. The company also cited supply-chain delays and component price increases.
- Other notable disclosures: The company entered a new 48-month facility lease beginning February 2023. Management reported effective disclosure controls and internal control over financial reporting as of March 31, 2023; the auditor was not engaged to audit internal controls. No material legal proceedings were reported.
Important facts for investors to verify
- Current cash runway, burn rate, and financing needs after the May 2023 offering, including the impact of warrants and subsequent share issuance.
- Actual progress and timing for completion of required device testing, FDA 510(k) submission, and clearance; no clearance had been obtained at year-end.
- Whether contract-manufacturer arrangements, production validation, component supply, and manufacturing scale-up are secured and on schedule.
- Evidence supporting reimbursement assumptions, proposed discounts, market-size estimates, and expected customer adoption; these are management’s plans and estimates, not reported results.
- Potential dilution from outstanding warrants, options, and future capital raises, and the continuing going-concern uncertainty.